

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 11TH August, 2025

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Newspaper Advertisement

Ref: Financial Results for the quarter ended June 30 2025

Dear Sir/Madam,

Dear Sir/ Madam,

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the copy of newspaper advertisement(s) of Financial Results of the Company for the Quarter ended June 30 , 2025, published in Financial Express and Jansatta on August 09, 2025. We request you to please take the same on record.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,
Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary
M. No. A32270



US PRESIDENT CALLED AN AD BY THE AUTOMAKER AS WOKE

Jaguar's new boss hits back at Trump

JAMIE NIMMO
August 8

JAGUAR LAND ROVER'S next chief executive officer shook off criticism from US President Donald Trump, insisting the carmaker is in good shape with customers responding positively to the polarizing Jaguar rebrand.

Trump this week accused the storied British manufacturer of being in "absolute turmoil" after what he called its "woke" advertisement released last year.

The video teaser featured bright colors and expressionless models dressed for the catwalk — but no vehicles. Jaguar also ditched its signature wild cat logo.

The automaker is sticking by the new look, said PB Balaji, chief financial officer of JLR

WAR OF WORDS

■ Trump this week accused Jaguar Land Rover of being in turmoil after its "woke" ad released last year

■ The video teaser featured bright colors, expressionless models dressed for catwalk — but no cars



■ Automaker sticking by new look, said PB Balaji, CFO of JLR parent Tata Motors, who is taking over as JLR's CEO in Nov

■ JLR has suffered from tariffs, which have hit deliveries of its luxury sport vehicles in US

parent Tata Motors, who is taking over as JLR's CEO in November.

"We have put our plans together, the cars are being revealed, they're getting exciting response from the customers on the ground," Balaji said on a call with reporters Friday. "Therefore that's what the

strategy is." Asked about Trump's remarks, Balaji said JLR's performance in a struggling global car industry proves the company is on the right track. "You need to compare our numbers vis-à-vis how others are delivering," he said.

His comments appear to

reject Trump's assertion that JLR's outgoing CEO Adrian Mardell resigned over the rebrand.

Jaguar isn't producing any cars until the new fully electric lineup is ready next year. It's targeting younger consumers, having previously been known as a status symbol for middle-

aged men in the UK.

The automaker, which revealed a concept car at the Miami Art Week last December, plans to sell fewer cars than in the past but at higher prices.

Still, Trump's outburst underscored how Jaguar's approach became a lightning rod. Its video drew fire from right-wing figures including Reform UK party leader Nigel Farage, who said it risked "going bust." Even Tesla Inc. CEO Elon Musk asked whether Jaguar still sold cars given the lack of them in the video.

JLR has suffered from Trump's trade tariffs, which have hit deliveries of its luxury sport vehicles in the US. That has weighed on Tata Motors' profit, which slumped by two-thirds in its latest quarter, the Indian group said Friday.

BLOOMBERG



This is the first tournament where Harika has chosen to travel with her daughter

FILE/EXPRESS

For Harika's 2-year-old, a peek into the GM life

VENKATA KRISHNA B
Chennai, August 8

TWO DAYS BEFORE the Chennai Grand Masters event began, Harika Dronavalli arrived at the playing venue to get a feel of it and brought with her, two-year-old daughter Hanvika. Inside the playing hall, her instincts took over as she made her daughter sit in her chair and recorded a video of her moving pieces. "That felt good, it's been like 25 years since I started playing chess internationally. It's a nice feeling that my daughter is coming and witnessing what I'm doing in my life," the Indian GM says.

This is the first tournament where Harika has chosen to travel with her daughter. When she won the bronze in the 2022 Chess Olympiad, Harika was pregnant, in her final trimester. Then, when she won gold at the 2024 Olympiad in Budapest, she had left her daughter in the care of her mother, sister, and grandmother for three weeks. It has been her routine when she travels abroad, but with this tournament happening in Chennai, it provided her with a rare luxury, to bring her daughter along, as she doesn't need to

worry about food and the weather. Even if she had a change of plan, Harika revealed she didn't need to fret too much about it as Hyderabad — where she currently lives — is closer to Chennai.

"I think any mother can relate to this. Guilt happens when you leave your child behind. I would love to have her everywhere. Even now, I don't think it's easy. But this (the tournament in Chennai) is so close to my place. I'm happy she could witness my life in a way," she says. After a brief pause, she makes it a point to remind Koneru Humpy that winning the silver at the FIDE Women's World Cup recently was no mean achievement. "With having a kid, family, so many responsibilities, the way she fought was just amazing. This is something that people should really understand, it is much more difficult for Humpy with the circumstances to still be there and be in the final," 34-year-old Harika says about her fellow veteran.

During overseas tournaments, Humpy has been Harika's most familiar companion for a long time. Though they don't exchange many notes, she

speaks about a professional relationship. "It's a very healthy competition over the years. When we go out of the country and have only two Indians in the tournament, you relate to them more, you understand each other's journeys. Now, being mothers and having a similar path, we understand each other and have a mutual respect and a healthy competition between us. We have had many meals together. But back then, Chess didn't have the limelight that it has right now," she says.

While the emergence of Divya Deshmukh, R Vaishali has expanded the Indian contingent, Harika prefers to leave the youngsters on their own and not bore them. "I have a very good rapport with Vaishali. After being a mother, the major thing you speak about is your children, so that's not something the youngsters can relate to me with," she says. Ask her about who she prefers to be a babysitter, she responds quickly. "Not Arjun (Erigaisi) for sure. I have seen Gukesh in Delhi when I got my daughter to meet the Prime Minister. I was very surprised with the way he handled kids. I genuinely didn't know, so I was very surprised. So I would say Gukesh."

A Swiss watchmaker's race to beat US tariffs

REUTERS
London/ Geneva, August 8

ASA US tariff deadline neared this week, Swiss watch manufacturer DuBois et fils rushed to ship five high-end watches worth thousands of dollars each to the US. By Wednesday the firm had blocked orders on its US website.

Now CEO Thomas Steine-mann is calculating the price hikes he'll need to make.

The whipsaw week for the Swiss horologist, as US President Donald Trump slapped a surprise 39% trade tariff on imports from the European country, underscores how businesses big and small are being forced to adapt and rejig operations under pressure.

DuBois et fils, founded in 1785, accelerated shipments on Monday from its factory in Muttenz, near Basel, to get through customs before the US tariff on imports from Switzerland came into force.

The 39% rate — up from

the baseline tariff rate of 10% since April — took effect on Thursday after the Swiss president came back from an emergency trip to Washington without a deal.

"For the watch industry it's a huge disaster," said Steine-mann, who explained that he'd blocked US orders because prices would need to be recalculated to account for tariffs. The firm would not soak up the hit, he said.

"The US was a big driver in the last two years. Now this kills a lot of the business."

His US prices were going to rise, he added. The DuBois DBF008 watch, for example, would likely go up to \$14,500, from \$10,800. America accounts for around 15% of the global sales of DuBois, which sells directly to US consumers.

The wider Swiss watch industry is feeling the pinch, planning price hikes, pausing US orders, and looking for alternative markets for its

TARIFF WOES

■ Swiss watch manufacturer DuBois et fils earlier this week had blocked orders on its US website

■ US President Donald Trump slapped 39% trade tariff on imports from European nation

■ Experts say the additional tariff is a huge disaster for the watch industry

■ The DuBois DBF008 watch, for example, would likely go up to \$14,500 from \$10,800



expensive, hand-made time-pieces. The country is home to brands such as Rolex, Patek Philippe, LVMH-owned Tag Heuer, Swatch-owned Omega and IWC Schaffhausen, owned by Richemont.

The US accounted for 17%

of Switzerland's total 26 billion Swiss francs (\$32 billion) of watch exports last year, according to the Federation of the Swiss Watch Industry. Exports to the US surged in April as watchmakers frontloaded shipments ahead of a first tar-

iff deadline.

Combined with a weaker dollar against the Swiss franc, the tariff hike will make Swiss watches some 65% more expensive on average for US consumers, estimated Amarildo Pilo, owner of Pilo & Co watchmakers.

He said that many brands had already shipped some product to the US in advance, but warned this was not a long-term solution.

The United States had been a market that everyone was focusing on recently and wanted to develop, he added. "My personal opinion is that what's going to happen is that Americans will no longer buy watches in the United States," said Pilo, who is also founder of the Swiss Independent Watchmakers Pavilion, which represents 28 independent brands.

"But those who want them and who like watches will buy them elsewhere. So honestly, it's a loss for the US."

Universal Sampo General Insurance Co. Ltd.

IRDAI Registration No.134 and Date of Registration with the IRDAI November 16, 2007 | CIN No. U66010MH2007PLC166770

Registered & Corporate Office : 8th Floor and 9th Floor (South Side), Commerz, International Business park, Oberoi Garden City, Off Western Express Highway, Goregaon East, Mumbai- 400063 • Website : www.universalsampo.com.

Unaudited Financial Results for the Quarter ended June 30, 2025

[Regulation 52(8), read with regulation 52(4) of the Listing Regulations] (₹ in Lakhs)

Sr. No	Particulars	Quarter Ended		Year Ended
		June 30, 2025	June 30, 2024	March 31, 2025
		Unaudited	Unaudited	Audited
1	Premium Income (Gross) (Refer note c)	131,305	112,646	509,264
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	7,507	5,080	25,063
3	Net Profit/ (Loss) for the period before tax (after Exceptional and/ or Extraordinary items)	7,507	5,080	25,063
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	5,613	3,554	18,986
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	NA	NA	NA
6	Equity Share Capital	36,818	36,818	36,818
7	Reserves (excluding Revaluation Reserve)	115,136	94,091	109,523
8	Securities Premium Account	16,762	16,762	16,762
9	Net worth	168,716	147,671	163,103
10	Paid up Debt Capital/ Outstanding Debt	15,000	-	15,000
11	Outstanding Redeemable Preference Shares	NA	NA	NA
12	Debt Equity Ratio (No. of times)	0.09	NA	0.09
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)			
	Basic:	1.52	0.97	5.16
	Diluted:	1.52	0.97	5.16
14	Capital Redemption Reserve	NA	NA	NA
15	Debt Service Coverage Ratio (No. of times)	21.40	NA	25.77
16	Interest Service Coverage Ratio (No. of times)	21.40	NA	25.77

Notes:

- This format is modified to reflect the terminology used in the Insurance Act IRDAI Regulations.
- The above is an extract of the detailed format of Quarterly/Annual Financial Results with the Stock Exchanges under Regulation 52(8), read with Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the Stock Exchange and the Company's website <https://www.universalsampo.com>.
- Premium income is gross of reinsurance and net of GST.
- Line Item No. 5 would be disclosed when Ind AS become applicable to Insurance companies.
- Net Profit/(Loss) before tax for the period is Profit/(Loss) before tax as appearing in Profit and Loss Account (Shareholders' account).
- Reserves are excluding Revaluation reserve and fair value change account.
- The Company has issued and allotted 15,000 Unsecured, rated, listed, redeemable, fully paid up, non-cumulative, subordinated, Non-Convertible Debentures (NCDs) in the nature of 'Subordinated Debt' in accordance with IRDAI (Registration, Capital Structure, Transfer of Shares and Amalgamation of Insurers) Regulations, 2024, the Companies Act, 2013 and the SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021, as amended, of face value of ₹1 lakh (each at par) aggregating to ₹15,000 lakhs through private placement on July 25, 2024.
- Debt-equity ratio is calculated as Total borrowings divided by Net worth.
- Debt service coverage ratio is calculated as Profit before interest and tax divided by interest expense together with principal repayments of long term debt during the period.
- Interest service coverage ratio is calculated as Profit before interest and tax divided by interest expense.

For and on behalf of the Board of Directors
Sd/-
Sharad Mather
Managing Director & CEO
DIN No. 06754740

Place : Mumbai
Date: August 07, 2025

Growing Together, Succeeding Together.

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER JUNE 30, 2025

(₹ in lacs except per share data)

Particulars	Standalone			Consolidated		
	Quarter Ended 30.06.2025 (Unaudited)	Quarter Ended 30.06.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)	Quarter Ended 30.06.2025 (Unaudited)	Quarter Ended 30.06.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)
1 Total Income from operations	42,514.22	38,425.62	1,69,157.22	44,490.16	40,169.55	1,75,895.92
2 Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	11,706.41	9,607.53	44,289.10	12,294.63	9,845.73	45,251.51
3 Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	11,706.41	9,607.53	44,289.10	12,294.63	9,845.73	45,251.51
4 Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	8,792.89	7,230.25	33,133.47	9,308.29	7,403.94	33,855.72
5 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8,705.10	7,101.03	32,978.76	9,239.57	7,266.36	33,720.25
6 Equity paid up share capital	5,066.29	4,798.58	5,066.29	5,066.29	4,798.58	5,066.29
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year			2,69,355.60	-	-	2,71,499.50
8 Earnings per share (Face Value of ₹ 5 each) (Quarterly not annualised) :						
Basic (₹)	8.68	7.53	33.40	9.19	7.71	34.13
Diluted (₹)	8.67	7.53	33.39	9.17	7.71	34.11

Notes:

- The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 08th August, 2025 and have also been limited reviewed by Statutory auditors of the company.
- The above is an extract of the detailed format of unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com.

Place: New Delhi
Date : 08th August 2025

POLY MEDICURE LIMITED
Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020,
Phone: 011-26321889, Fax: 011-26321894
Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com,
CIN: L40300DL1995PLC068923

By order of the Board
Sd/-
 Himanshu Baird
Managing Director

Growing Together,
Succeeding Together.



30 जून, 2025 की तिमाही के लिए अलेखापरीक्षित एकल और समेकित वित्तीय परिणामों का विवरण

(प्रति शेयर औंकों को छोड़कर, लाखों रुपये में)

विवरण	स्टैंडअलोन			समेकित		
	समाप्त तिमाही 30.06.2025 (अलेखापरीक्षित)	समाप्त तिमाही 30.06.2024 (अलेखापरीक्षित)	समाप्त वर्ष 31.03.2025 (लेखापरीक्षित)	समाप्त तिमाही 30.06.2025 (अलेखापरीक्षित)	समाप्त तिमाही 30.06.2024 (अलेखापरीक्षित)	समाप्त वर्ष 31.03.2025 (लेखापरीक्षित)
1. परिचालन से कुल आय	42,514.22	38,425.62	1,69,157.22	44,490.16	40,169.55	1,75,895.92
2. अवधि के लिए शुद्ध लाभ/(हानि) (कर, असाधारण और/या असाधारण मदों से पहले)	11,706.41	9,607.53	44,289.10	12,294.63	9,845.73	45,251.51
3. कर से पहले की अवधि के लिए शुद्ध लाभ/(हानि) (असाधारण और/या असाधारण मदों के बाद)	11,706.41	9,607.53	44,289.10	12,294.63	9,845.73	45,251.51
4. कर के बाद की अवधि के लिए शुद्ध लाभ/(हानि) (असाधारण और/या असाधारण मदों के बाद)	8,792.89	7,230.25	33,133.47	9,308.29	7,403.94	33,855.72
5. अवधि के लिए कुल व्यापक आय रूबरुबि के लिए लाभ/(हानि) (कर के बाद) और अन्य व्यापक आय (कर के बाद) सहित	8,705.10	7,101.03	32,978.76	9,239.57	7,266.36	33,720.25
6. इक्विटी शेयर रोजर पूंजी	5,066.29	4,798.58	5,066.29	5,066.29	4,798.58	5,066.29
7. पिछले वर्ष की लेखापरीक्षित बैलेंस शीट में दर्शाए अनुसार आरक्षित निधियों (पुनर्मूल्यांकन आरक्षित निधि को छोड़कर)			2,69,355.60	-		2,71,499.50
8. प्रति शेयर आय (प्रत्येक का अंकित मूल्य 5 रुपये) (तिमाही, वार्षिकीकृत नहीं) :						
बेसिक(रुपये)	8.68	7.53	33.40	9.19	7.71	34.13
तनु (रुपये)	8.67	7.53	33.39	9.17	7.71	34.11

टिप्पणियाँ:
 1. उपरोक्त अलेखापरीक्षित एकल और समेकित परिणामों की समीक्षा और अनुसंधान लेखापरीक्षा समिति द्वारा की गई और निदेशक मंडल द्वारा 08 अगस्त, 2025 को आयोजित अपनी-अपनी बैठकों में अनुमोदित किया गया तथा कंपनी के सांविधिक लेखा परीक्षकों द्वारा भी सीमित समीक्षा की गई है।
 2. उपरोक्त 30 जून, 2025 को समाप्त तिमाही के अलेखापरीक्षित एकल और समेकित वित्तीय परिणामों के विस्तृत प्रारूप का एक अंश है, जो सेबी (सूचीबद्धता दायित्व और प्रकटीकरण आवश्यकताएँ) विनियम, 2015 के विनियम 33 के अंतर्गत स्टॉक एक्सचेंजों में दाखिल किया गया है। अलेखापरीक्षित वित्तीय परिणामों का पूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइटों www.bseindia.com, www.nseindia.com और कंपनी की वेबसाइट www.polymedure.com पर उपलब्ध है।

स्थान: नई दिल्ली
दिनांक: 08 अगस्त 2025
 पॉली मेडिक्योर लिमिटेड
 पंजीकृत कार्यालय: 232बी, तृतीय तल, ओखला औद्योगिक एस्टेट, फेज 111, नई दिल्ली - 110020,
 फोन: 011-26321889, फैक्स: 011-26321894 वेबसाइट: www.polymedure.com,
 ईमेल: investorcare@polymedure.com,
 सीआईएन: L40300DL1995PLC066923

बोर्ड के आदेशानुसार
 हस्ताक्षरकर्ता/-
 हिमांशु बैद
 प्रबंध निदेशक



AKUMS DRUGS AND PHARMACEUTICALS LIMITED
 CIN: L24239DL2004PLC125888
 Regd. Office: 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (India)
 Corporate Office: Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
 Phone: +91-11-69041000, Fax: +91-11-27023256, Email: akumsho@akums.net, Website: www.akums.in

UNAUDITED (STANDALONE & CONSOLIDATED) FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2025

The Board of Directors of Akums Drugs and Pharmaceuticals Limited ("the Company"), on recommendation of the audit committee, at its meeting held on 8th August, 2025, approved the unaudited (Standalone & Consolidated) Financial Results for the quarter ended 30th June, 2025.

The complete Financial Results along with the Limited Reviewed Reports are available on the website of stock exchanges at www.nseindia.com and www.bseindia.com and also posted on the website of the company and can be accessed at <https://www.akums.in/investors/financial-report/>.

For More Information Please Scan:



For Akums Drugs and Pharmaceuticals Limited
 Sd/- Sanjeev Jain Managing Director
 Sd/- Sandeep Jain Managing Director
Date: 8 August, 2025
Place: Delhi

ACE एक्शन कंस्ट्रक्शन इक्विपमेंट लिमिटेड

सीआईएन: L74899HR1995PLC053860
 रजि. कार्यालय: दुधौला लिक रोड, दुधौला, जिला पलवल-121102, हरियाणा
 फोन: +91-1275-280111 (50 लाइनें), फैक्स: +91-1275-280133 वेबसाइट: www.ace-cranes.com ईमेल: cs@ace-cranes.com

30 जून, 2025 को समाप्त तिमाही के लिए स्टैंडअलोन और समेकित अलेखापरीक्षित वित्तीय विवरणों के सार

क्र. सं.	विवरण	स्टैंडअलोन		समेकित					
		समाप्त तिमाही 30.06.2025 (अलेखापरीक्षित)	समाप्त तिमाही 31.03.2025 (अलेखापरीक्षित)	समाप्त तिमाही 30.06.2024 (अलेखापरीक्षित)	समाप्त तिमाही 31.03.2025 (अलेखापरीक्षित)	समाप्त तिमाही 30.06.2025 (अलेखापरीक्षित)	समाप्त तिमाही 31.03.2025 (अलेखापरीक्षित)	समाप्त तिमाही 30.06.2024 (अलेखापरीक्षित)	समाप्त तिमाही 31.03.2025 (अलेखापरीक्षित)
1.	परिचालन से कुल आय	65194	95925	73363	54311	12772	16089	11199	54912
2.	अवधि के लिए शुद्ध लाभ (कर, असाधारण मदों और/या असाधारण मदों से पूर्व)	12644	16050	11142	54311	12772	16089	11199	54912
3.	कर पूर्व अवधि के लिए शुद्ध लाभ (कर, असाधारण मदों और/या असाधारण मदों के बाद)	12644	16050	11142	54311	9772	11856	11199	54912
4.	अवधि के लिए शुद्ध लाभ (कर, असाधारण और/या असाधारण मदों के बाद)	9683	11841	8371	40364	9772	11856	8418	40924
5.	अवधि के लिए कुल व्यापक आय (कर के बाद)	9683	11814	8371	40337	9772	11816	8418	40922
6.	इक्विटी शेयर पूंजी (प्रत्येक का अंकित मूल्य रु. 2/-)	2382	2382	2382	2382	2382	2382	2382	2382
7.	प्रति शेयर आय (प्रत्येक का अंकित मूल्य रु. 2/-) (वार्षिकीकृत नहीं है):								
1.	मूल-	8.14	9.95	7.03	33.92	8.21	9.97	7.07	34.39
2.	परिसमाप्त-	8.13	9.95	7.03	33.91	8.21	9.96	7.07	34.37

टिप्पणियाँ:
 (अ) उपरोक्त 30 जून, 2025 को समाप्त तिमाही और वर्ष के लिए सेबी (सूचीबद्धता दायित्व और प्रकटीकरण आवश्यकताएँ) विनियम, 2015 के विनियम 33 के तहत स्टॉक एक्सचेंजों में दायर विस्तृत प्रारूप का एक अंश है। पूर्ण तिमाही के परिणामों का प्रारूप स्टॉक एक्सचेंज की वेबसाइट (www.nseindia.com, www.bseindia.com) और कंपनी की वेबसाइट www.ace-cranes.com पर उपलब्ध है।
 (ब) उपरोक्त वित्तीय परिणामों की समीक्षा लेखा परीक्षा समिति द्वारा की गई है और कंपनी के निदेशक मंडल द्वारा 08 अगस्त, 2025 को आयोजित उनकी संवैधानिक बैठक में स्वीकृति प्रदान की गई है।
 (स) 30 जून 2025 और 31 मार्च 2025 को समाप्त तिमाही के लिए गैर नियंत्रित ब्याज पर आरोप्य लाभ और कुल व्यापक आय का क्रमशः 33,000 रुपये और 18,000 रुपये राउंड ऑफ करने के कारण (लाभ में) ख़ुलासा नहीं किया गया है।

स्थान: फरीदाबाद
 दिनांक: 08 अगस्त, 2025



कृते एक्शन कंस्ट्रक्शन इक्विपमेंट लिमिटेड
 हस्ताक्षरकर्ता/-
 विजय अग्रवाल
 अध्यक्ष एवं प्रबंध निदेशक

भाई-बहन के अटूट प्रेम का पावन पर्व

जहाँ हर धागे में बँधा है सुरक्षा और स्नेह का विश्वास।

रक्षाबंधन
 की हार्दिक शुभकामनाएँ!

9 अगस्त, 2025



"बहन और भाई के बीच अटूट विश्वास और अगाध प्रेम को समर्पित रक्षाबंधन का ये पावन पर्व, हमारी संस्कृति का पवित्र प्रतिबिंब है। मेरी कामना है, यह पर्व हर किसी के जीवन में स्नेह, सद्भाव और सौहार्द की भावना को और प्रगाढ़ करे"

-नरेन्द्र मोदी, प्रधानमंत्री

